MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday

MAIA Biotechnology (NYSEAMERICAN:MAIA) is anticipated to announce its Q3 2026 resultson Friday, November 6th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, analysts expect MAIA Biotechnology to post ($0.54) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.

MAIA Biotechnology Stock Up 5.6%

MAIA Biotechnology stock opened at $1.14 on Thursday. The firm has a market cap of $70.38 million, a price-to-earnings ratio of -1.84 and a beta of 0.28. MAIA Biotechnology has a 52 week low of $0.87 and a 52 week high of $3.19. The business’s 50-day moving average price is $1.23 and its 200 day moving average price is $1.45.

Insider Activity at MAIA Biotechnology

In other news, Director Ramiro Guerrero bought 37,595 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were acquired at an average price of $1.32 per share, for a total transaction of $49,625.40. Following the completion of the transaction, the director directly owned 773,296 shares in the company, valued at $1,020,750.72. The trade was a 5.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Vlad Vitoc bought 73,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was purchased at an average price of $1.37 per share, for a total transaction of $100,010.00. Following the transaction, the chief executive officer owned 1,049,121 shares of the company’s stock, valued at approximately $1,437,295.77. This represents a 7.48% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 258,078 shares of company stock valued at $352,426. 19.81% of the stock is owned by company insiders.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.

MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.